What differences in the data and results would you predict to see if you had been able to use Mastoparan-1 instead? Would you predict Mastoparan-X in conjunction with Mastoparan-1 to be more successful or just Mastoparan-1?
We predict that potentially Mastoparan-1 will be just as if not more successful as a good portion of our scientific references indicated that it was Mastoparan-1 that exhibited antibiotic properties.
Furthermore, we also know that Mastoparan-1 targets the LPS of certain bacteria, whereas we could not determine the mechanism by which Mastoparan-X affected bacteria.
Mastoparan-X could then potentially be used to in an In Vivo assay in which it’s injected into a small animal to measure its effects within a biological system against the target bacteria, and whether or not it can survive the biological system and still effectively affect the target bacteria.
This indicates that the data and results for the compound are considered significant, and unlikely to have occurred by chance if they occur below or above two standard deviations away from the mean of the negative control. If above, then it indicates that our compound possesses growth-enhancement qualities. if below, then it indicates our compound possess inhibitory properties.
The last class of antibiotics discovered was the lipopeptide class. The Company was Eli Lilly and Company, with Daptomycin being the last antibiotic drug discovered for this class, being initially discovered in1983, and approved by the FDA in 2003.
Our Max Dose assay was created by diluting the stock concentration to 1uL/mL. This was our max concentration we diluted our stock concentration to for our experiment as that’s what our laboratory protocol directed us to do. Since our project design did not involve clinical trials, we were unable to determine the Max concentration a patient could receive, however a Max dose trial would be performed during clinical trials with patients to determine the maximum dosage a patient could receive while experiencing minimal negative side effects.
We are not entirely sure of all the differences between Mastoparan-X and Mastoparan-1. What we know is that Mastoparan-1 targets the LPS of certain bacteria, we do not know the mechanism by which Mastoparan-X affects bacteria. As far as structure goes, we know that Mastoparan-X possesses a sulfur atom, but we are unsure how Mastoparan-X structurally differs. Deciphering and analyzing these differences is something we aspire to discover in a future research study.
The first way in which Mastoparan-X can be studied is by further verifying whether it is a hit at its maximum dose as we were unable to truly verify it were a hit. If it is, then we would like to determine if whether or not Mastoparan-X is more effective than Mastoparan-1 with regards to its antibiotic properties. We could also tamper with the chemistry of Mastoparan-X, by modifying its functional groups to, for example, make it possess a greater affinity for the target bacteria.
We suspect that we may have either added too high a concentration of Mastoparan-X to the plate, or that we may have accidently used ampicillin, our positive control, by mistake, along with adding too high a concentration of our negative control in its respective wells.
curesymposium.org 
What differences in the data and results would you predict to see if you had been able to use Mastoparan-1 instead? Would you predict Mastoparan-X in conjunction with Mastoparan-1 to be more successful or just Mastoparan-1?
LikeLike
We predict that potentially Mastoparan-1 will be just as if not more successful as a good portion of our scientific references indicated that it was Mastoparan-1 that exhibited antibiotic properties.
LikeLike
Furthermore, we also know that Mastoparan-1 targets the LPS in certain bacteria, we do not know the mechanism for how Mastoparan-X affects bacteria.
LikeLike
Furthermore, we also know that Mastoparan-1 targets the LPS of certain bacteria, whereas we could not determine the mechanism by which Mastoparan-X affected bacteria.
LikeLike
If Mastoparan-X is a Hit how could it be used in the future?
LikeLike
Mastoparan-X could then potentially be used to in an In Vivo assay in which it’s injected into a small animal to measure its effects within a biological system against the target bacteria, and whether or not it can survive the biological system and still effectively affect the target bacteria.
LikeLike
Why is a “hit” considered to be plus or minus two standard deviations from the mean of the negative control?
LikeLike
This indicates that the data and results for the compound are considered significant, and unlikely to have occurred by chance if they occur below or above two standard deviations away from the mean of the negative control. If above, then it indicates that our compound possesses growth-enhancement qualities. if below, then it indicates our compound possess inhibitory properties.
LikeLike
In the 1980s, which major pharma company found the last class of antibiotics? Have any been found since then by anyone else?
LikeLike
The last class of antibiotics discovered was the lipopeptide class. The Company was Eli Lilly and Company, with Daptomycin being the last antibiotic drug discovered for this class, being initially discovered in1983, and approved by the FDA in 2003.
LikeLike
How did you come up with the max dose for a patient for Mastoparan-X?
LikeLike
Our Max Dose assay was created by diluting the stock concentration to 1uL/mL. This was our max concentration we diluted our stock concentration to for our experiment as that’s what our laboratory protocol directed us to do. Since our project design did not involve clinical trials, we were unable to determine the Max concentration a patient could receive, however a Max dose trial would be performed during clinical trials with patients to determine the maximum dosage a patient could receive while experiencing minimal negative side effects.
LikeLike
What are the differences between Mastoparan-X and Mastoparan-1
LikeLike
We are not entirely sure of all the differences between Mastoparan-X and Mastoparan-1. What we know is that Mastoparan-1 targets the LPS of certain bacteria, we do not know the mechanism by which Mastoparan-X affects bacteria. As far as structure goes, we know that Mastoparan-X possesses a sulfur atom, but we are unsure how Mastoparan-X structurally differs. Deciphering and analyzing these differences is something we aspire to discover in a future research study.
LikeLike
How could Mastoparan-X be studied or used in terms of future antibiotic research and drug development?
LikeLike
The first way in which Mastoparan-X can be studied is by further verifying whether it is a hit at its maximum dose as we were unable to truly verify it were a hit. If it is, then we would like to determine if whether or not Mastoparan-X is more effective than Mastoparan-1 with regards to its antibiotic properties. We could also tamper with the chemistry of Mastoparan-X, by modifying its functional groups to, for example, make it possess a greater affinity for the target bacteria.
LikeLike
How could Mastoparan-X be studied and used in future antibiotic research and drug development?
LikeLike
What do you suppose caused the outlier result in the max dosage (4:08)?
LikeLike
We suspect that we may have either added too high a concentration of Mastoparan-X to the plate, or that we may have accidently used ampicillin, our positive control, by mistake, along with adding too high a concentration of our negative control in its respective wells.
LikeLike